You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)公佈百悦澤®用於治療出現呼吸窘迫的新冠肺炎患者的2期臨牀試驗最新進展
格隆匯 04-09 06:20

格隆匯 4 月 9日丨百濟神州(06160.HK)於2021年4月8日(美國東部時間)宣佈,一項旨在評估百悦澤® (澤布替尼)對比安慰劑針對患有新冠肺炎且需非機械通氣輔助供氧的住院患者的2期臨牀試驗未達到無呼吸衰竭生存或吸氧天數減少的並列主要有效性終點。百悦澤®在該試驗中未出現新的安全警示。

百濟神州血液學首席醫學官黃蔚娟表示:“通過百濟神州團隊和我們的研究合作伙伴的努力,我們得以進一步瞭解BTK抑制劑針對新冠病毒的潛力,我也為此感到驕傲。儘管這項2期臨牀試驗的結果不盡如人意,但為評估百悦澤®能否為全球抗擊新冠肺炎做貢獻而啟動該項臨牀試驗的速度之快令人欣慰。百濟神州的使命自始至終都是在嚴謹的科學指導下以及在精心設計和開展的試驗中尋找説明全球患者的療法。百濟神州預計將在未來以科學報吿或學術論文的形式遞交相關數據。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account